Woman's Breast Health Supplement, IoGen™, Available to Public in February From Symbollon Pharmaceuticals

MEDFIELD, MA--(Marketwire - January 21, 2010) - Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA)
(www.symbollon.com) has announced today that the retail launch of
IoGen™, its dietary supplement for women's breast health, will commence
in February. IoGen™ is the first dietary supplement formulated to
promote breast health for women. Initially, the Company plans to market
IoGen™ through its own retail web site, which is currently being
developed by Atech Solutions. This rapid launch schedule was made possible
when the Company reacquired the significant IoGen™ finished goods
inventory previously purchased by its former distributor. In preparation
of the launch, Symbollon has partnered with ProLog Logistics
(www.prologlogistics.com), a state-of-the-art fulfillment center with a
complete customer service support division.

"We are moving very quickly to prepare the IoGen™ product launch,"
stated Paul C. Desjourdy, President and Chief Executive Officer of
Symbollon. "We recently repurchased the IoGen finished goods inventory from
our previous distributor. This significant inventory will advance our
expected retail launch of IoGen™ by months. By partnering with Atech
Solutions for the web site development and ProLog Logistics for complete
state-of-the-art fulfillment and customer service needs, we believe that we
will provide women looking to improve their breast health with a responsive
and customer focused buying experience. Making this important female
health product available to women is an important first step in helping
improve the lives of millions of women concerned with their overall breast
health."

Since its inception in 1996, ProLog Logistics has remained focused on
delivering high-quality and cost-effective operational out-sourcing
solutions. Utilizing two state-of-the-art distribution facilities, coupled
with a centralized call center, ProLog is ideally positioned to meet the
operational needs of its clients.

Symbollon is a specialty biotechnology company focused on the development
and commercialization of proprietary products based on its molecular iodine
technology for women's healthcare and antimicrobials uses. For more
information about Symbollon, please visit the company's website at
http://www.symbollon.com.

Forward Looking Statement: This news release contains statements by the
Company that involve risks and uncertainties and may constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements reflect management's current
views and are based on certain assumptions. Actual results could differ
materially from those currently anticipated as a result of a number of
factors, including, but not limited to, the risks and uncertainties
associated with whether (i) we will be able to successfully commercialize
IoGen, (ii) Symbollon will be able to obtain the resources necessary to
continue operations as a going concern, (iii) the Company will be able to
enter into new arrangements with corporate partners, (iv) management and
the Board of Directors will be able to maximize shareholder value by
leveraging the Company's proprietary technology, and (v) such other factors
as may be disclosed from time-to-time in the Company's reports as filed
with the Securities and Exchange Commission.